Business Insider

Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity

BERKELEY, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and ...
Business Insider

Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or ...

BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of ...
AZoNano

Enhancing Antitumor Immunity: A Novel Cancer Vaccine Combining Nano-11 and ADU-S100

In a recent article published in npj Vaccines, researchers detailed the development of a novel cancer vaccine that combines a plant-derived nanoparticle adjuvant, Nano-11, with a clinically tested ...